PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges

McGowan, E; Lin, Q; Ma, G; Yin, H; Chen, S; Lin, Y

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges

McGowan, E

Lin, Q Ma, G Yin, H Chen, S Lin, Y

Permalink

Publication Type:: Journal Article
Citation:: Biomedicine and Pharmacotherapy, 2020, 121
Issue Date:: 2020-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted ManuscriptAdobe PDF (966.4 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	McGowan, E https://orcid.org/0000-0001-6371-3751	en_US
dc.contributor.author	Lin, Q	en_US
dc.contributor.author	Ma, G	en_US
dc.contributor.author	Yin, H	en_US
dc.contributor.author	Chen, S	en_US
dc.contributor.author	Lin, Y	en_US
dc.date.available	2019-10-30	en_US
dc.date.issued	2020-01-01	en_US
dc.identifier.citation	Biomedicine and Pharmacotherapy, 2020, 121	en_US
dc.identifier.issn	0753-3322	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136855
dc.description.abstract	© 2019 The Authors Unprecedented efficacy of chimeric antigen receptor (CAR) T cell therapy in the treatment of hematologic malignancies brings new hope for patients with many cancer types including solid tumors. However, the challenges for CAR-T cell therapy in eradicating solid tumors are immense. To overcome these seemingly intractable hurdles, more “powerful” CAR-T cells with enhanced antitumor efficacy are required. Emerging data support that the anti-tumor activity of CAR-T cells can be enhanced significantly without evident toxicity through simultaneous PD-1 disruption by genome editing. This review focuses on the current progress of PD-1 gene disrupted CAR-T cells in cancer therapy. Here we discuss key rationales for this new combination strategy and summarize the available pre-clinical studies. An update is provided on human clinical studies and available registered cancer clinical trials using CAR-T cells with PD-1 disruption. Future prospects and challenges are also discussed.	en_US
dc.relation.ispartof	Biomedicine and Pharmacotherapy	en_US
dc.relation.isbasedon	10.1016/j.biopha.2019.109625	en_US
dc.subject.classification	Oncology & Carcinogenesis	en_US
dc.title	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges	en_US
dc.type	Journal Article
utslib.citation.volume	121	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access
pubs.publication-status	Published	en_US
pubs.volume	121	en_US

Abstract:

© 2019 The Authors Unprecedented efficacy of chimeric antigen receptor (CAR) T cell therapy in the treatment of hematologic malignancies brings new hope for patients with many cancer types including solid tumors. However, the challenges for CAR-T cell therapy in eradicating solid tumors are immense. To overcome these seemingly intractable hurdles, more “powerful” CAR-T cells with enhanced antitumor efficacy are required. Emerging data support that the anti-tumor activity of CAR-T cells can be enhanced significantly without evident toxicity through simultaneous PD-1 disruption by genome editing. This review focuses on the current progress of PD-1 gene disrupted CAR-T cells in cancer therapy. Here we discuss key rationales for this new combination strategy and summarize the available pre-clinical studies. An update is provided on human clinical studies and available registered cancer clinical trials using CAR-T cells with PD-1 disruption. Future prospects and challenges are also discussed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136855